Mercado Global de Febre Hemorrágica Chapare (CHHF) – Tendências do setor e previsão para 2030

Análise e dimensão do mercado da febre hemorrágica Chapare (CHHF)

Em 2020, devido à propagação da COVID-19, os Centros de Controlo e Prevenção de Doenças (CDC) dos EUA começaram a investigar outros vírus mortais e descobriram o vírus chapare. O vírus pode ser transmitido de humano para humano em contacto direto com um roedor infetado. Foi testemunhado pela primeira vez na Bolívia, onde inicialmente resultou numa pandemia e mais tarde foi controlado num instante. Aumento da ocorrência de doenças infeciosas, aumento dos gastos com a saúde impulsionam o crescimento do mercado.

A Data Bridge Market Research analisa uma taxa de crescimento no mercado da febre hemorrágica do chapare (CHHF) no período de previsão 2023-2030. O CAGR esperado do mercado da febre hemorrágica do chapare (CHHF) tende a rondar os 4,50% no período de previsão mencionado. O valor de mercado é de 1,54 mil milhões de dólares em 2022 e cresceria até 2,2 mil milhões de dólares até 2030. Além dos insights sobre cenários de mercado, como o valor de mercado, taxa de crescimento, segmentação, cobertura geográfica e grandes players , os relatórios de mercado com curadoria da Data Bridge Market Research também incluem análise especializada aprofundada, epidemiologia de pacientes, análise de pipeline, análise de preços e estrutura regulamentar.

Âmbito e segmentação do mercado da febre hemorrágica Chapare (CHHF)

Market Definition

Chapare hemorrhagic fever (CHHF) is a type of viral infectious disease that is caused by chapare virus. It belongs to the Arenaviridae family. This is an animal borne virus and zoonotic. CHHF is an acute viral hemorrhagic fever which is typically characterised by arthralgia, myalgia, fever, abdominal pain, skin rashes, vomiting, bleeding gums and multiple hemorrhagic signs. It typically causes a hemorrhagic fever similar to Ebola along with pain behind the eyes.  

Chapare Hemorrhagic Fever (CHHF) Market Dynamics

Drivers

• Increased cases of chapare hemorrhagic fever (CHHF)

The increasing cases of chapare hemorrhagic fever (CHHF) among diverse parts of the country are increasing market growth. Ebola virus has killed 12 of 23 infected people in Guinea in 2021 and six of 12 in the DR Congo. There have been several cases and outbreaks of Marburg virus disease, with Uganda reporting small outbreaks in 2012 and major outbreaks occurring in central and southern Africa. Therefore, it demands advanced treatment and boosts the growth of the market.

• Increase in elderly population

As per the research, the aging population is more susceptible to this disease. As per the Aging World reports from 2015, there were around 562 million people 65 and older globally, which increased the disease's occurrence and boosted the growth of the hemorrhagic fever treatment market.

Opportunities

• Growing acquisitions and collaborations

The growing acquisitions of diverse market players are creating much opportunities for the market growth. For instance, Teva Pharmaceuticals acquired Allergan’s generics business in August 2016. This acquisition has helped the company deliver the highest-quality generic medicines at the most reasonable prices, and unlocking value to patients, healthcare systems and investors globally.

Restraints/Challenges

• Lack of proper cure

The lack of treatments for chapare hemorrhagic fever (CHHF) is hindering the growth of the market. The treatment is expensive because of the lack of FDA-approved drugs, which leads to lower affordability. No appropriate treatment can cure chapare hemorrhagic fever (CHHF)s and immunizations exist for only two of the many chapare hemorrhagic fever (CHHF) deterring the market growth.

• Increased generic influx

The patent expiry of most of the drugs has led to the way for the entry of generics into the market. The extreme use of generic medicine can impede the demand for several branded drugs, therefore affecting the market.

This chapare hemorrhagic fever (CHHF) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the chapare hemorrhagic fever (CHHF) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Chapare Hemorrhagic Fever (CHHF) Market Scope

The chapare hemorrhagic fever (CHHF) market is segmented on the basis of treatment, transmission, dosage, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Intravenous Therapy
• Pain Relievers
• Transfusions
• Management of hydration
• Others

Transmission

• Direct Contact
• Indirect Contact

Dosage

• Tablet
• Injection
• Others

Route of Administration

• Oral
• Intravenous
• Others

End-Users

• Hospitals
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Chapare Hemorrhagic Fever (CHHF) Market Regional Analysis/Insights

The chapare hemorrhagic fever (CHHF) market is analyzed and market size insights and trends are provided by treatment, transmission, dosage, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the chapare hemorrhagic fever (CHHF) market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is the dominating region due to the rising occurrence of haemophilus influenzae infection and advanced healthcare facilities.

Asia-Pacific is considered the growing region because of the higher cases of cardiovascular diseases and rapidly aging population.

A secção do país do relatório também fornece fatores individuais de impacto no mercado e alterações na regulamentação do mercado interno que impactam as tendências atuais e futuras do mercado. Além disso, são considerados a presença e disponibilidade de marcas globais e os desafios enfrentados devido à grande ou escassa concorrência de marcas locais e nacionais, o impacto das tarifas nacionais e das rotas comerciais, ao mesmo tempo que se fornece uma análise de previsão dos dados do país.   

Cenário competitivo e análise global da quota de mercado da febre hemorrágica do Chapare (CHHF)

O panorama competitivo do mercado da febre hemorrágica chapare (CHHF) fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença global, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa , lançamento de produto, largura e amplitude do produto, aplicação domínio. Os dados acima fornecidos estão apenas relacionados com o foco das empresas relacionado com o mercado da febre hemorrágica chapare (CHHF)

Os principais players que trabalham no mercado da febre hemorrágica do chapare (CHHF) incluem:

• Novartis AG (Suíça)
• Endo International Inc (Irlanda)
• Teva Pharmaceutical Industries Ltd (Israel)
• Glenmark Pharmaceuticals Ltd (Índia)
• Cipla Inc (Índia)
• Dr Reddy's Laboratories Ltd (Índia)
• Abbott (EUA)
• F. Hoffmann-La Roche Ltd (Suíça)
• Pfizer Inc (EUA)
• Grupo Zydus (Índia)
• Lupin (Índia)
• Amorphex Therapeutics Holdings, Inc (EUA)
• Bausch Health Companies Inc. (Canadá)
• WEX Pharmaceuticals Inc (Canadá)
• Zynerba Pharmaceuticals, Inc (EUA)
• Estrellas Life Sciences Private Limited (EUA)

SKU-66167